The new PreserveRx program from Prime Therapeutics looks to help plan sponsors deal with high-cost gene therapies, Fierce Healthcare reports. According to the report, members of the new program will pay a monthly fee in order to be protected from the crippling costs of expensive drugs like […]
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership
HealthEconomics.Com© LLC and Scientist.Com are partnering to streamline HEOR and real-world evidence sourcing in the global HEOR and RWE community and pharma market with the new HEOR & RWE Marketplace. The marketplace offers stakeholders an online platform to both evaluate and purchase HEOR […]
Bricker Talks Wave 2 of COVID-19
How can payers and providers best prepare for a second wave in the COVID-19 pandemic? Compass Professional Health Services CMO Eric Bricker in a Relentless Health Value podcast discusses what could be a new normal in the health care landscape. To listen to the podcast, click here. […]
Blog Post Highlights Impact Coronavirus Could Have on New Drug Launches
A recent blog post on Tribeca Knowledge outlines some of the key challenges pharmaceutical companies face regarding drug launches in the midst of the COVID-19 pandemic. Drug launches outside the COVID-19 arena "are under threat of delay, postponement, dilution or worse," the author, Andre Moa, […]
Shkreli Seeks Furlough to Research Potential COVID-19 Treatments
Disgraced biotech entrepreneur Martin Shkreli is requesting a 3-month furlough to research potential treatments for COVID-19, STAT reports. In a scientific paper published online, Shkreli lays out how he could contribute to the pandemic response. "As a successful two-time biopharma […]
ISPOR 2020 Goes Virtual
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is moving its annual meeting into the virtual space in response to the COVID-19 pandemic, the society announced Monday, April 6. According to the announcement, the online event will kick off May 18. ISPOR says the […]
AMCP to Supreme Court: Ruling Against PCMA Could Raise Health Costs
The Academy of Managed Care Pharmacy (AMCP) in an amicus brief filed in the Supreme Court tells the court ruling against the Pharmaceutical Care Management Association (PCMA) in Rutledge v. PCMA could have a negative impact on costs and patient outcomes. According to a press release, the case […]
MSK’s Bach Talks High-Value Drug Development
Memorial Sloan Kettering Cancer Center's Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value drug development. Bach said while it's a complex effort, the goal is to pay as little as possible to pharmaceutical companies to "incentivize high-value […]
ISPOR Task Force Publishes New Good Practices Reports
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) Value of Information Analysis Emerging Good Practices Task Force has had two good practices reports published in Value in Health since February. The following are the published reports: Value of Information […]
Calculating Costs, Benefits of Lockdowns
How do economists calculate the value of preventing COVID-19 deaths? The authors of a recent article published on Forbes outline the methods economists use to project the potential impact on costs. While putting a dollar amount on a human life may make some "uncomfortable," the authors write, […]
PRMA’s Chadwick Talks Digital Tech’s Impact on Market Access
PRMA Consulting HTA Manager Claire Chadwick outlines how digital technology is changing the face of the market access landscape in the latest tHEORetically Speaking blog post. HealthEconomics.Com LLC CEO and HE Institute Principal Researcher Patti Peeples conducted the interview. Chadwick […]
Article Outlines How Health Plans Utilize RWE for Specialty Drug Coverage
Health plans' use of real-world evidence for specialty drug coverage decisions is generally varied in terms of the number and type of studies cited, according to a recent article published by Wiley. The authors, Ari Panzer et al., used data from the Tufts Medical Center Specialty Drug Evidence […]
Waystar: Poor Price Transparency is ‘Single Biggest Issue’ in Patient’s Financial Experience
In a sponsored article on HealthLeaders Media, Waystar outlines the patient's need for more "financial clarity" during their health care journey. Waystar points to a 2019 published in JAMA which suggests it's becoming more likely for patients to be billed by an out-of-network provider despite […]
eyeforpharma Philadelphia Pivots to Virtual Event
In response to the COVID-19 outbreak, eyeforpharma is transitioning its eyeforpharma Philadelphia conference to a free, online event. The 4-day virtual conference is set to kick off April 14, and will feature more than 70 sessions and more than 70 speakers. "The Covid-19 coronavirus has […]
NICE Publishes COVID-19 Guidelines
The National Institute for Health and Care Excellence (NICE) on March 21 published a new set of guidelines that address the management of patients with COVID-19, and those without. NICE says the guidelines aim to bolster patient safety, as well as facilitate the "best use of NHS resources and […]
Webinar – Faster to Market: Transforming HEOR & RWE Using Virtual Sourcing
Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want to connect with new buyers in this age of reduced face-to-face business development? Some of the biggest challenges in HEOR & RWE are long contracting time, lack of RFI […]
Blog Post Mulls Indirect Benefits in Value Assessments
A recent blog post published on Health Affairs highlights some key reasons why indirect benefits should be factored into value assessments. The authors, National Pharmaceutical Council Vice President of Research Michael Ciarametaro et al., suggest indirect benefits in value assessments have "the […]
Predictions for RWE in 2020
A recent article published on PharmaTimes looks at what the future may hold for real-world evidence amid rising interest in the pharmaceutical industry. The author, Verantos CEO Dan Riskin, widespread efforts to establish robust RWE "provides a significant opportunity to refine the standard of […]
Lin: Clinical Practice Guidelines Not Broken
Family physician and Common Sense Family Doctor blogger Kenneth Lin in a recent post published on MedPage Today writes that while "clinical practice guidelines have problems, they're not broken." Lin was referencing the title of a Health Affairs blog post, "Fixing Clinical Practice Guidelines," […]
Vogenberg Talks Digital Health Tools
The latest Relentless Health Value podcast features Institute for Integrated Health Principal Randy Vogenberg, who discusses the selection of digital health tools for formularies. Vogenberg is also the co-leader for the National Employer Initiative on Specialty Pharmacy and cofounder of the […]
ICER Indefinitely Postpones Public Meetings, Expands Assessment Timelines
In response to the COVID-19 pandemic, the Institute for Clinical and Economic Review (ICER) announced it would indefinitely postpone several public meetings and push out the timelines for assessments. The following details were provided in a press release sent out Wednesday morning: Sickle […]
AMCP Cancels Annual Meeting
The Academy of Managed Care Pharmacy (AMCP) has canceled its annual meeting, which was set to begin April 21, saying that holding the meeting amid the COVID-19 outbreak has "become impermissible." "We deeply appreciate your patience as AMCP leaders and staff have monitored and responded to this […]
Pfizer Offers Its Resources in Fight Against Coronavirus
Pfizer is entering the fight against coronavirus after announcing it would offer its resources for wider use, FiercePharma reports. The drugmaker is also calling on other drugmakers to collaborate, according to the report. "Pfizer calls on all members of the innovation ecosystem—from large […]
ICER Posts Reports Outlining Two Planned Reviews
The Institute for Clinical and Economic Review (ICER) on Friday, March 13, posted two new draft scoping documents outlining planned reviews of bladder cancer treatments, as well as digital apps used for opioid use disorder. According to a press release, ICER is planning to review nadofaragene […]
U.S. Looks to Limit Out-of-Pocket Costs for Insulin Under Medicare
The Trump administration announced a new plan to limit the out-of-pocket costs for insulin to $35 month for Medicare patients, Reuters reports. According to the report, the Centers for Disease Control and Prevention is setting up a testing environment for the payment plan. "While Medicare […]
RWE 2020 Postponed Until Later This Year
The Real-World Evidence 2020: Rare Diseases and Innovative Therapies event has been postponed to later this year in response to the ongoing impact of COVID-19. The event was originally scheduled to begin April 1 in London, U.K. Future Science Events Managing Director Lauren Pulling in an email […]
Webinar to Outline Key Takeaways of ICER’s Updated Value Framework
Boston Healthcare Associates is slated to highlight the Institute for Clinical and Economic Review's (ICER) updated value assessment framework in an upcoming webinar. The event is set to begin 11 a.m. EST March 25. Boston Healthcare Associates' Jordan Hinahara, senior manager, and Thomas Goss, […]
AMCP Seeks Session Proposals for Nexus 2020
The Academy of Managed Care Pharmacy (AMCP) has issued a call for education session proposals as it gears up for its Nexus 2020 meeting, which is set to begin Oct. 20 in Las Vegas. The deadline proposals is April 8. According to AMCP, presentations must: Be based on and reference the best […]
Welltok’s Smith Discusses SDOH
Welltok Consumer Journey Director Jodi Smith in a recent write up published on Modern Healthcare Executive says payers and providers can take aim at social determinants of health (SDOH) by combining environmental and lifestyle data points with traditional data. "The more health plans and […]
Cantrell Highlights Updated AMCP Format
Academy of Managed Care Pharmacy (AMCP) CEO Susan Cantrell in a blog post says the AMCP Format 4.1 features new sections that highlight the evidence needs of health care decision-makers regarding unapproved products. The updated format, which was presented during Nexus 2019, factors in current […]
